IMMUNOPHENOTYPE OF SOLID TUMORS AND TUMOR METABOLIC REPROGRAMMING

Simple item page
dc.contributor.advisorBingham, Jon-Paul
dc.contributor.authorzitello, emory david
dc.contributor.departmentMolecular Biosciences and Bioengineering
dc.date.accessioned2024-07-02T23:41:10Z
dc.date.issued2024
dc.description.degreePh.D.
dc.embargo.liftdate2026-06-24
dc.identifier.urihttps://hdl.handle.net/10125/108315
dc.subjectMedicine
dc.subjectImmunology
dc.subjectBioinformatics
dc.subjectbioinformatics
dc.subjectbiologic therapies
dc.subjectimmunophenotype
dc.subjectmolecular diagnostics
dc.subjectpan-cancer
dc.subjecttumor immunology
dc.titleIMMUNOPHENOTYPE OF SOLID TUMORS AND TUMOR METABOLIC REPROGRAMMING
dc.typeThesis
dcterms.abstractABSTRACTWith the technological advances in biotechnology that have been made high-throughput measurement of nucleic acids feasible and affordable, the tumor microenvironment (TME) has been intensively studied. Advances in therapy have made pharmacologic treatment of cancer more effective than ever before. However, in consideration of the expense of the new class of monoclonal immunotherapeutic antibodies, their occasionally serious side effect profile, and a somewhat limited spectrum of activity among patient cohorts, there has come a great demand to understand the factors which make individual cases of cancer differ. Many approaches to address the issue of individual patient response to immunomodulatory antibodies have been devised. Both traditional, bench-based approaches and more modern, bioinformatical solutions have yielded important insights into the problem. Unfortunately, many difficult and important questions have remained unexplained. In particular, a general theory that is capable of explaining the broadest similarity of observed clinical responses to therapy with monoclonal immunotherapeutic agents across dissimilar patient cohorts that identifies a clear relationship to cellular and molecular features has been elusive. Understanding the most important concepts involved in tumor immunology requires drawing together some intermediate and detailed knowledge from several subdisciplines in biology and clinical medicine. In the studies presented here, elements of bioinformatic data analysis, details of immunological function, and knowledge of cellular and molecular processes relevant to cancer are reviewed in terms of published literature as an introduction. In a second segment, these topics of perceived relevance to studies of cancer are then highlighted with presentations of new findings based upon a novel bioinformatic approach. A summary is presented in Chapter 3 containing a brief discussion of how these findings impact the field with reference to current knowledge and practice, while a series of Appendices further substantiate the importance of these findings with brief details of a variety of related results.
dcterms.extent201 pages
dcterms.languageen
dcterms.publisherUniversity of Hawai'i at Manoa
dcterms.rightsAll UHM dissertations and theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission from the copyright owner.
dcterms.typeText
local.identifier.alturihttp://dissertations.umi.com/hawii:12037

Files

Original bundle
Now showing 1 - 4 of 4
No Thumbnail Available
Name:
zitello_hawii_0085A_12037.pdf
Size:
10.76 MB
Format:
Adobe Portable Document Format
Download (Embargo until 2026-06-24)
No Thumbnail Available
Name:
Supplementary file 1 - Markers of M1, M2 and Tumor-associated macrophages.xlsx
Size:
15.54 KB
Format:
Microsoft Excel XML
Download (Embargo until 2026-06-24)
No Thumbnail Available
Name:
Supplementary file 2 - Immunotherapeutic Targets and other Molecular Markers of Immune Cells.xlsx
Size:
9.84 KB
Format:
Microsoft Excel XML
Download (Embargo until 2026-06-24)
No Thumbnail Available
Name:
Supplementary file 3.xlsx
Size:
17.98 KB
Format:
Microsoft Excel XML
Download (Embargo until 2026-06-24)

Collections

Ph.D. - Molecular Biosciences and Bioengineering